{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:27Z","timestamp":1792788507374,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA012197"],"award-info":[{"award-number":["P30CA012197"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258692"],"award-info":[{"award-number":["R01CA258692"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Orin Smith Family Foundation","id":[{"id":"https:\/\/ror.org\/00vjsmz50","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Appendiceal neoplasms are a group of rare, heterogeneous tumors that exhibit varying malignant potential. Systemic treatment options for disseminated appendiceal cancer are limited. We sought to review rates of mutations that may indicate potential roles for routine next-generation sequencing to identify targetable therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An analysis of 916 appendiceal tumor samples submitted to American Association for Cancer Research Genomics Evidence Neoplasia Information Exchange (GENIE) consortium was performed to compare patient demographics and the rates of mutations that may confer drug susceptibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Low-grade appendiceal mucinous neoplasms (LAMNs) had the lowest mutations per specimen (4.5 \u00b1 4.6,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.01) and the highest percentage of KRAS mutations (88.9%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01). In KRAS-mutated LAMNs, 92% occurred at codon G12, with 56.5% at G12V and 39.1% at G12D. In total, 5.7%, 29.7%, 53.0%, and 71.8% of goblet cell, signet ring cell, appendiceal, and mucinous adenocarcinomas, respectively, had KRAS mutations. Across all appendiceal tumors, only a limited number had drug-targetable mutations within each gene evaluated: 7.0% KRAS G12C mutations, 26.4% GNAS mutations, 6.9% PIK3CA mutations, and 3.5% DNA mismatch repair gene (MLH1, MSH2, MSH6, and PMS2) mutations. Collectively, 21.5% of appendiceal cancer cases were associated with at least one or more gene mutations with drug targeting potential, and 4.3% of cases had multiple targetable mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although mutations suggesting available drug targeting occur at low frequencies in appendiceal tumors, minimal overlap of these mutations results in a sizeable subpopulation of patients that may benefit from targeted therapies. Next-generation sequencing may enable tailored therapeutic approaches for disseminated appendiceal cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19702-1","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:33:27Z","timestamp":1790692407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Sequencing Identifies Key Targetable Mutations in the Treatment of Appendiceal Neoplasms"],"prefix":"10.1245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4681-8054","authenticated-orcid":false,"given":"Rui","family":"Zheng-Pywell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore J.","family":"Lumia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidy Cos","family":"Felipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Gironda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"10","key":"19702_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/jclinpath-2012-200843","volume":"65","author":"NJ Carr","year":"2012","unstructured":"Carr NJ, Finch J, Ilesley IC, et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol. 2012;65(10):919\u201323. https:\/\/doi.org\/10.1136\/jclinpath-2012-200843.","journal-title":"J Clin Pathol"},{"issue":"4","key":"19702_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11605-014-2726-7","volume":"19","author":"S Marmor","year":"2015","unstructured":"Marmor S, Portschy PR, Tuttle TM, Virnig BA. The rise in appendiceal cancer incidence: 2000\u20132009. J Gastrointest Surg. 2015;19(4):743\u201350. https:\/\/doi.org\/10.1007\/s11605-014-2726-7.","journal-title":"J Gastrointest Surg"},{"issue":"7","key":"19702_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.7326\/annals-24-02479","volume":"178","author":"AN Holowatyj","year":"2025","unstructured":"Holowatyj AN, Washington MK, Goldberg RM, Murphy CC. Birth Cohort Effects in Appendiceal Adenocarcinoma Incidence Across the United States. Ann Intern Med. 2025;178(7):957\u201362. https:\/\/doi.org\/10.7326\/annals-24-02479.","journal-title":"Ann Intern Med"},{"issue":"5","key":"19702_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1245\/s10434-012-2238-1","volume":"19","author":"KK Turaga","year":"2012","unstructured":"Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol. 2012;19(5):1379\u201385. https:\/\/doi.org\/10.1245\/s10434-012-2238-1.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"19702_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s11605-008-0774-6","volume":"13","author":"AN Trivedi","year":"2009","unstructured":"Trivedi AN, Levine EA, Mishra G. Adenocarcinoma of the appendix is rarely detected by colonoscopy. J Gastrointest Surg. 2009;13(4):668\u201375. https:\/\/doi.org\/10.1007\/s11605-008-0774-6.","journal-title":"J Gastrointest Surg"},{"issue":"10","key":"19702_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23270","volume":"63","author":"J Doll","year":"2024","unstructured":"Doll J, Maurus K, K\u00f6hler F, et al. Molecular profiling of low-grade Appendiceal mucinous neoplasms (LAMN). Genes Chromosomes Cancer. 2024;63(10):e23270. https:\/\/doi.org\/10.1002\/gcc.23270.","journal-title":"Genes Chromosomes Cancer"},{"key":"19702_CR7","doi-asserted-by":"publisher","unstructured":"Levine EA, Blazer DG, 3rd, Kim MK, et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg 2012; 214(4):599-606; discussion 06-7 https:\/\/doi.org\/10.1016\/j.jamcollsurg.2011.12.028","DOI":"10.1016\/j.jamcollsurg.2011.12.028"},{"issue":"4","key":"19702_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2015.12.012","volume":"222","author":"EA Levine","year":"2016","unstructured":"Levine EA, Votanopoulos KI, Qasem SA, et al. Prognostic molecular subtypes of low-grade cancer of the appendix. J Am Coll Surg. 2016;222(4):493\u2013503. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2015.12.012.","journal-title":"J Am Coll Surg"},{"issue":"9","key":"19702_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1634\/theoncologist.2017-0081","volume":"22","author":"WL Shaib","year":"2017","unstructured":"Shaib WL, Assi R, Shamseddine A, et al. Appendiceal mucinous neoplasms: diagnosis and management. Oncologist. 2017;22(9):1107\u201316. https:\/\/doi.org\/10.1634\/theoncologist.2017-0081.","journal-title":"Oncologist"},{"issue":"2","key":"19702_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00595-019-01856-z","volume":"50","author":"T Kitai","year":"2020","unstructured":"Kitai T, Yamanaka K, Sugimoto N, Inamoto O. Surgical management for peritoneal carcinomatosis of appendiceal origin with a high-tumor burden. Surg Today. 2020;50(2):171\u20137. https:\/\/doi.org\/10.1007\/s00595-019-01856-z.","journal-title":"Surg Today"},{"issue":"1","key":"19702_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1245\/s10434-019-07932-5","volume":"27","author":"K Zambrano-Vera","year":"2020","unstructured":"Zambrano-Vera K, Sardi A, Munoz-Zuluaga C, et al. Outcomes in peritoneal carcinomatosis from appendiceal goblet cell carcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC). Ann Surg Oncol. 2020;27(1):179\u201387. https:\/\/doi.org\/10.1245\/s10434-019-07932-5.","journal-title":"Ann Surg Oncol"},{"key":"19702_CR12","doi-asserted-by":"publisher","unstructured":"Smith JW, Kemeny N, Caldwell C, Banner P, Sigurdson E, Huvos A. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992;70(2):396-401 https:\/\/doi.org\/10.1002\/1097-0142(19920715)70:2<396::aid-cncr2820700205>3.0.co;2-a.","DOI":"10.1002\/1097-0142(19920715)70:2<396::aid-cncr2820700205>3.0.co;2-a"},{"key":"19702_CR13","doi-asserted-by":"publisher","unstructured":"Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219(2):112-9 https:\/\/doi.org\/10.1097\/00000658-199402000-00002.","DOI":"10.1097\/00000658-199402000-00002"},{"issue":"1","key":"19702_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3978\/j.issn.2078-6891.2015.101","volume":"7","author":"KA Cummins","year":"2016","unstructured":"Cummins KA, Russell GB, Votanopoulos KI, Shen P, Stewart JH, Levine EA. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). J Gastrointest Oncol. 2016;7(1):3\u20139. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.101.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"19702_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1245\/s10434-014-4147-y","volume":"22","author":"KI Votanopoulos","year":"2015","unstructured":"Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015;22(4):1274\u20139. https:\/\/doi.org\/10.1245\/s10434-014-4147-y.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"19702_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/jso.25599","volume":"120","author":"P Lu","year":"2019","unstructured":"Lu P, Fields AC, Meyerhardt JA, et al. Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma. J Surg Oncol. 2019;120(3):446\u201351. https:\/\/doi.org\/10.1002\/jso.25599.","journal-title":"J Surg Oncol"},{"issue":"7","key":"19702_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jso.23547","volume":"109","author":"AU Blackham","year":"2014","unstructured":"Blackham AU, Swett K, Eng C, et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014;109(7):740\u20135. https:\/\/doi.org\/10.1002\/jso.23547.","journal-title":"J Surg Oncol"},{"issue":"1","key":"19702_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11605-019-04336-4","volume":"24","author":"NC Levinsky","year":"2020","unstructured":"Levinsky NC, Morris MC, Wima K, et al. Should we be doing cytoreductive surgery with HIPEC for signet ring cell appendiceal adenocarcinoma? a study from the US HIPEC collaborative. J Gastrointest Surg. 2020;24(1):155\u201364. https:\/\/doi.org\/10.1007\/s11605-019-04336-4.","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"19702_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/jso.25967","volume":"122","author":"JC Chen","year":"2020","unstructured":"Chen JC, Beal EW, Hays J, Pawlik TM, Abdel-Misih S, Cloyd JM. Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer. J Surg Oncol. 2020;122(3):388\u201398. https:\/\/doi.org\/10.1002\/jso.25967.","journal-title":"J Surg Oncol"},{"issue":"2","key":"19702_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1245\/s10434-007-9691-2","volume":"15","author":"D Baratti","year":"2008","unstructured":"Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15(2):526\u201334. https:\/\/doi.org\/10.1245\/s10434-007-9691-2.","journal-title":"Ann Surg Oncol"},{"key":"19702_CR21","unstructured":"AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through an International Consortium, Cancer Discov. 2017 Aug; 7(8):818-831 GENIE cohort v16.0."},{"issue":"3","key":"19702_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/21541248.2016.1212689","volume":"8","author":"J Cisowski","year":"2017","unstructured":"Cisowski J, Bergo MO. What makes oncogenes mutually exclusive? Small GTPases. 2017;8(3):187\u201392. https:\/\/doi.org\/10.1080\/21541248.2016.1212689.","journal-title":"Small GTPases"},{"key":"19702_CR23","doi-asserted-by":"publisher","unstructured":"Ang CS, Shen JP, Hardy-Abeloos CJ, et al. Genomic Landscape of Appendiceal Neoplasms. JCO Precis Oncol 2018; 2 https:\/\/doi.org\/10.1200\/po.17.00302","DOI":"10.1200\/po.17.00302"},{"issue":"10","key":"19702_CR24","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1158\/1078-0432.Ccr-18-3388","volume":"25","author":"R Tokunaga","year":"2019","unstructured":"Tokunaga R, Xiu J, Johnston C, et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clin Cancer Res. 2019;25(10):3096\u2013103. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3388.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"19702_CR25","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1373\/clinchem.2014.225565","volume":"60","author":"X Liu","year":"2014","unstructured":"Liu X, Mody K, de Abreu FB, et al. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin Chem. 2014;60(7):1004\u201311. https:\/\/doi.org\/10.1373\/clinchem.2014.225565.","journal-title":"Clin Chem"},{"key":"19702_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/srep00161","volume":"1","author":"T Furukawa","year":"2011","unstructured":"Furukawa T, Kuboki Y, Tanji E, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep. 2011;1:161. https:\/\/doi.org\/10.1038\/srep00161.","journal-title":"Sci Rep"},{"issue":"12","key":"19702_CR27","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/modpathol.2017.88","volume":"30","author":"LL Ritterhouse","year":"2017","unstructured":"Ritterhouse LL, Vivero M, Mino-Kenudson M, et al. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. Mod Pathol. 2017;30(12):1720\u20137. https:\/\/doi.org\/10.1038\/modpathol.2017.88.","journal-title":"Mod Pathol"},{"issue":"1","key":"19702_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12967-016-0877-x","volume":"14","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio F, Berenato R, Maggi C, et al. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. J Transl Med. 2016;14(1):125. https:\/\/doi.org\/10.1186\/s12967-016-0877-x.","journal-title":"J Transl Med"},{"issue":"20","key":"19702_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70340","volume":"13","author":"J Gibson","year":"2024","unstructured":"Gibson J, Pengelly RJ, Mirandari A, et al. Targeted genetic sequencing analysis of 223 Cases of pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy shows survival related to GNAS and KRAS status. Cancer Med. 2024;13(20):e70340. https:\/\/doi.org\/10.1002\/cam4.70340.","journal-title":"Cancer Med"},{"issue":"3","key":"19702_CR30","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1245\/s10434-007-9699-7","volume":"15","author":"JM Logan-Collins","year":"2008","unstructured":"Logan-Collins JM, Lowy AM, Robinson-Smith TM, et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol. 2008;15(3):738\u201344. https:\/\/doi.org\/10.1245\/s10434-007-9699-7.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"19702_CR31","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1245\/s10434-014-4335-9","volume":"22","author":"JH Choe","year":"2015","unstructured":"Choe JH, Overman MJ, Fournier KF, et al. Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms. Ann Surg Oncol. 2015;22(8):2578\u201384. https:\/\/doi.org\/10.1245\/s10434-014-4335-9.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"19702_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.clcc.2018.07.011","volume":"17","author":"G Glockzin","year":"2018","unstructured":"Glockzin G, Zeman F, Croner RS, et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 COMBATAC trial. Clin Colorectal Cancer. 2018;17(4):285\u201396. https:\/\/doi.org\/10.1016\/j.clcc.2018.07.011.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"19702_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/cncr.24715","volume":"116","author":"JF Shapiro","year":"2010","unstructured":"Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116(2):316\u201322. https:\/\/doi.org\/10.1002\/cncr.24715.","journal-title":"Cancer"},{"issue":"12","key":"19702_CR34","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1634\/theoncologist.2013-0186","volume":"18","author":"KP Raghav","year":"2013","unstructured":"Raghav KP, Shetty AV, Kazmi SM, et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013;18(12):1270\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2013-0186.","journal-title":"Oncologist"},{"issue":"25","key":"19702_CR35","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/jco.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, Yaeger R, Spira AI, et al. Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation. J Clin Oncol. 2023;41(25):4097\u2013106. https:\/\/doi.org\/10.1200\/jco.23.00434.","journal-title":"J Clin Oncol"},{"issue":"13","key":"19702_CR36","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) inhibition with Sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1917239.","journal-title":"N Engl J Med"},{"issue":"10","key":"19702_CR37","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med. 2022;28(10):2171\u201382. https:\/\/doi.org\/10.1038\/s41591-022-02007-7.","journal-title":"Nat Med"},{"issue":"6","key":"19702_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/jco.24.00511","volume":"43","author":"J Weitz","year":"2025","unstructured":"Weitz J, Nishizaki D, Liau J, et al. Cyclin-dependent kinase 4\/6 inhibition as a novel therapy for peritoneal mucinous carcinomatosis with GNAS mutations. J Clin Oncol. 2025;43(6):705\u201315. https:\/\/doi.org\/10.1200\/jco.24.00511.","journal-title":"J Clin Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19702-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19702-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19702-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:12:09Z","timestamp":1790741529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19702-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":38,"alternative-id":["19702"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19702-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}